Antibe Therapeutics Company Profile (CVE:ATE)

Analyst Ratings

Consensus Ratings for Antibe Therapeutics (CVE:ATE) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Antibe Therapeutics (CVE:ATE)
Show:
DateFirmActionRatingPrice TargetActions
3/13/2015M PartnersReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/26/2014 forward)

Earnings

Earnings History for Antibe Therapeutics (CVE:ATE)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Antibe Therapeutics (CVE:ATE)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Antibe Therapeutics (CVE:ATE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Antibe Therapeutics (CVE:ATE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
3/29/2016Scott Wilson CurtisInsiderBuy19,500C$0.13C$2,535.00Tweet This Trade  Share This Trade on StockTwits
3/28/2016Scott Wilson CurtisInsiderBuy30,500C$0.13C$3,965.00Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Antibe Therapeutics (CVE:ATE)
DateHeadline
07/19/16 08:49 AMAntibe Therapeutics Announces the Appointment of New Board Member and Provides Update on Phase 2 Trial of ATB-346
06/22/16 07:46 PMAntibe Therapeutics Completes Final Closing of Non-Brokered Private Placement Bringing Total Proceeds to $1,455,000
06/10/16 08:28 PMAntibe Therapeutics Raises $968,500 in First Tranche of Non-Brokered Private Placement
05/30/16 09:50 AMAntibe Therapeutics Presenting Update on ATB-346 at International Hydrogen Sulfide Conference - TORONTO--(BUSINESS WIRE)--Antibe Therapeutics Inc. ("Antibe") (TSXV:ATE, OTCQX:ATBPF) will be front-and-centre at the 4 th International Conference on the Biology of Hydrogen Sulfide, to be held in Naples, Italy from June 3 rd to 5th. The company’s ...
05/02/16 10:57 AMAntibe Therapeutics To Present At 2016 Bloom Burton & Co. Healthcare Investor Conference - Antibe Therapeutics Inc. ("Antibe") (TSXV: ATE, OTCQX: ATBPF), a commercial-stage pharmaceutical growth company, is pleased to announce that CEO Daniel Legault will be presenting at the fifth annual Bloom Burton & Co. Healthcare Investor Conference in ...
04/18/16 10:28 AMAntibe Therapeutics Announces the Launch of PentOS OI(TM) Putty, a High-Quality Bone Graft Substitute for Oral and Maxillofacial Surgery - Antibe Therapeutics Inc. ("Antibe") (TSXV:ATE, OTCQX:ATBPF) today announced that its subsidiary Citagenix Inc. (“Citagenix”) has launched PentOS OI™ Putty, the first product of a new family of bone graft substitutes that have a proven ability to form ...
04/18/16 10:28 AMAntibe Therapeutics Announces the Launch of PentOS OI™ Putty, a High-Quality Bone Graft Substitute for Oral and Maxillofacial Surgery - TORONTO--(BUSINESS WIRE)--Antibe Therapeutics Inc. ("Antibe") (TSXV:ATE, OTCQX:ATBPF) today announced that its subsidiary Citagenix Inc. (“Citagenix”) has launched PentOS OI™ Putty, the first product of a new family of bone graft substitutes that ...
03/10/16 09:03 AMAntibe Therapeutics Announces Grant Of Stock Options - Antibe Therapeutics Inc. ("Antibe") (TSXV: ATE, OTCQX: ATBPF) announces that it has granted its directors, officers and employees options to purchase a total of 6,751,000 common shares of Antibe pursuant to the Corporation's stock option plan. Each option ...
03/07/16 08:59 AMAntibe Therapeutics' ATB-346 Receives Approval For Phase 2 Clinical Trial In Osteoarthritis Patients - Antibe Therapeutics Inc. ("Antibe") (TSXV:ATE, OTCQX:ATBPF) has received approval from Health Canada to conduct a Phase 2 trial of its lead drug, ATB-346, in patients with osteoarthritis of the knee. The primary endpoints of the study will be clinical ...
03/05/16 08:38 AMAntibe Therapeutics Receives Approval to Proceed to Phase 2 Clinical Trial - TORONTO--(BUSINESS WIRE)--Antibe Therapeutics Inc. ("Antibe") (TSXV:ATE, OTCQX:ATBPF) is pleased to announce that it has received approval from Health Canada to initiate a Phase 2 trial. Antibe submitted an application to Health Canada to perform a trial ...
02/29/16 08:58 PMAntibe Therapeutics Reports Q3 2016 Interim Financial And Operating Results - Antibe Therapeutics Inc. ("Antibe") (TSXV:ATE, OTCQX:ATBPF) filed its financial and operating results Monday, February 29 for the fiscal quarter ended December 31, 2015. The Corporation's unaudited Q3 2016 financial statements and MD&A are available on SEDAR.
02/25/16 08:36 AMProfound Preventative and Restorative Effects of ATB-346 in Mice with Genetic Predisposition to Intestinal Cancer - About Antibe Therapeutics Inc. (TSXV: ATE, OTCQX: ATBPF) Antibe develops safer medicines for pain and inflammation. Antibe’s technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce a patented, improved medicine.
02/06/16 07:54 AMAntibe Therapeutics Inc. (ATE.V) - Antibe Therapeutics Inc. originates, develops, and out-licenses patent protected pharmaceuticals. The company s lead compound is the ATB-346, a hydrogen sulfide-releasing derivative of naproxen that is in Phase I clinical study for the treatment of ...
02/02/16 06:42 PMAntibe Therapeutics Closes Acquisition Of Minority Interest In Citagenix Inc. - Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV:ATE, OTCQX:ATBPF) announces that it has completed the acquisition of the remainder 15% minority interest in Citagenix Inc. ("Citagenix"), a Montreal-based sales and distribution company with a ...
01/28/16 08:04 AMAntibe Therapeutics Announces Payment in Kind Election - Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV:ATE, OTCQX:ATBPF) announces it has elected to pay in kind all interest due January 15, 2016 under the Company’s 10% senior secured convertible debentures due October 15, 2018 (the "Debentures").

Social

About Antibe Therapeutics

Antibe Therapeutics Inc. is a Canada-based company that originates, develops and out-licenses pharmaceuticals that are improved versions of existing drugs. The Company's drug design methodologies involve chemically linking a base drug to its hydrogen sulfide-releasing molecule. The Company's lead compound, ATB-346, combines hydrogen sulfide (H2S) with naproxen, which is an approved, marketed and off patent non-steroidal anti-inflammatory drug (NSAID). The Company has conducted multiple pre-clinical studies, combining the attributes of H2S with naproxen, which have demonstrated that ATB-346, which has therapeutic efficacy that is equal to or greater than that of naproxen while demonstrating an improved side-effect profile versus naproxen and other commonly used NSAID treatments for pain associated with, amongst other conditions, osteoarthritis. Additionally, the Company investigates other assets in its pipeline, as well as additional development opportunities to which it has access.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: CVE
  • Symbol: ATE
  • CUSIP:
Key Metrics:
  • Previous Close: $0.00
  • 50 Day Moving Average: $N/A
  • 200 Day Moving Average: $N/A
  • P/E Ratio: N/A
  • P/E Growth: N/A
  • Market Cap: $N/A
  • Current Year EPS Consensus Estimate: $-0.10 EPS
  • Next Year EPS Consensus Estimate: $N/A EPS
Additional Links:
Antibe Therapeutics (CVE:ATE) Chart for Tuesday, July, 26, 2016